Journal
OPEN FORUM INFECTIOUS DISEASES
Volume 8, Issue 7, Pages -Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/ofid/ofab274
Keywords
COVID-19; liver-type fatty acid binding protein; urinary 11-dehydro- thromboxane B2; urinary 8-hydroxy-2'-deoxyguanosine
Categories
Funding
- Platelet and Thrombosis Research, LLC, Baltimore, MD, USA
Ask authors/readers for more resources
Higher levels of urine 11-dehydro-thromboxane B-2 and liver-type fatty acid binding protein at hospitalization were associated with longer hospital stay, more thrombotic events, and higher mortality in COVID-19 patients, suggesting their potential utility as early prognostic biomarkers.
Urine 11-dehydro-thromboxane B-2 (u11-dh-TxB(2)), 8-hydroxy-2'-deoxyguanosine (8-OHdG), and liver-type fatty acid binding protein levels (L-FABP) at the time of hospitalization were higher in coronavirus disease 2019 (COVID-19) patients with adverse events vs without events. Higher u11-dh-TxB(2) and L-FABP levels were associated with longer hospitalization, more thrombotic events, and greater mortality, providing evidence for potential utility as early prognostic biomarkers for COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
